CurrentAvMedPolicy N/A

Prior Authorization and Step-Edit Criteria for Saphnelo (anifrolumab) IV Infusion

Prior authorization and step-edit criteria for Saphnelo (anifrolumab) intravenous infusion for treatment of moderate-to-severe systemic lupus erythematosus (SLE) for AvMed members; defines documentation, prescriber, trial, and exclusion requirements.

Policy Summary

PayerAvMed

PolicyPrior Authorization and Step-Edit Criteria for Saphnelo (anifrolumab) IV Infusion

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionSubmit a provider-signed prior authorization request with supporting documentation including labs confirming autoantibody-positive SLE, disease activity scores (SLEDAI-2K or BILAG), prior therapy history, and current concomitant therapies.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

300 mg q4wrecommended dosage

12 moinitial auth

12 moreauthorization

≥18age

positiveautoantibody requirement

Coverage Criteria for Saphnelo (anifrolumab) IV

Initial Therapy

Covered when ALL of the following are met

Initial Authorization (must meet ALL): Prescribed by or in consultation with a rheumatologist or nephrologist; Member is 18 years of age or older; Diagnosis of autoantibody-positive SLE confirmed by ONE of the following: ANA titer ≥ 1:80, anti-dsDNA ≥ 30 IU/mL, or elevated anti-Smith per reference range (submit lab results); Active moderate-to-severe SLE activity confirmed by ONE of the following: SLEDAI-2K score ≥ 6 OR BILAG 2004 organ domain score ≥ 1A or ≥ 2B (submit results); Member has tried THREE of the following therapies (verified by chart notes or pharmacy paid claims): mycophenolate, hydroxychloroquine, azathioprine, cyclophosphamide, methotrexate, cyclosporine, corticosteroids, or other (specify); Member is currently established on at least ONE of the listed background therapies for the last 90 days and will continue that therapy if approved for Saphnelo.

Initial approval duration: 12 months

Continuation Therapy

Reauthorization covered when ALL of the following are met

Reauthorization: Member has experienced a positive clinical response to Saphnelo as confirmed by ONE of the following: reduction of baseline BILAG A to B/C/D and baseline BILAG B to C/D with no BILAG worsening in other organ systems (worsening defined as ≥ 1 new BILAG A or ≥ 2 new BILAG B), OR no worsening from baseline in SLEDAI-2K (worsening = increase > 0 points); AND the member has absence of intolerable side effects such as serious or recurrent infections, malignancy, severe hypersensitivity/anaphylaxis, or intolerable infusion reactions.

Policy Summary

PayerAvMed

PolicyPrior Authorization and Step-Edit Criteria for Saphnelo (anifrolumab) IV Infusion

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coding, Dosing, and Clinical Thresholds

Covered HCPCS CodeHCPCSCovered

J0491

Anifrolumab-fnia injection (Saphnelo) — billed as medical

SLEDAI-2K — disease activity threshold

SLEDAI-2K score thresholdSLEDAI-2K score of >= 6 required to document active moderate-to-severe SLE

Use for initial authorizationSubmit SLEDAI-2K result with PA request to support initial approval (12 months)

Use for reauthorizationReauthorization requires no worsening from baseline in SLEDAI-2K (increase >0 defines worsening)

BILAG 2004 organ domain score — disease activity threshold

BILAG 2004 organ domain score thresholdBILAG 2004 organ domain score of >= 1A or >= 2B required to document active moderate-to-severe SLE

Use for initial authorizationSubmit BILAG 2004 organ domain scores with PA request to support initial approval (12 months)

Use for reauthorizationReauthorization evidence may include reduction in BILAG scores (e.g., baseline A to B/C/D or baseline B to C/D) without BILAG worsening

Recommended dosage — dosing recommendation

Recommended dose and schedule300 mg every 4 weeks (IV) — recommended dosage

Length of initial approvalInitial authorization documented as 12 months in the policy

Documentation noteInclude dosing schedule on PA form; incomplete drug info can delay authorization

Autoantibody thresholds — laboratory criteria for autoantibody-positive SLE

ANA thresholdAnti-nuclear antibody (ANA) titer >= 1:80 qualifies for autoantibody-positive SLE

Anti-dsDNA thresholdAnti-double stranded DNA (anti-dsDNA) >= 30 IU/mL qualifies for autoantibody-positive SLE

Anti-Smith thresholdAnti-Smith (anti-SM) antibody levels elevated according to laboratory reference range qualifies for autoantibody-positive SLE

Provider Requirements and Prior Authorization Workflow

Prior Authorization

Prior Authorization Required

Prior Authorization Required: A completed, provider-signed prior authorization request is required for medical benefit drugs. The prescribing physician must sign and clearly print their name (preprinted stamps not valid) on the request. Incomplete, illegible, or incorrect forms—including missing phone/fax numbers—can delay processing or lead to denial.

Fax completed form to 1-877-535-1391
Initial approval length: 12 months (see criteria)

Step Therapy

Step Therapy — Prior Trials Required

Step therapy: Prior trials of specified therapies must be documented. Member must have tried and failed (or have contraindication to) the required medications; trials will be verified using pharmacy claims and/or submitted chart notes.

Required trial of three agents (examples listed): mycophenolate, hydroxychloroquine, azathioprine, cyclophosphamide, methotrexate, cyclosporine, corticosteroids
Must document current background therapy taken ≥90 days if applicable

Documentation Required

Required Documentation for Prior Authorization

Required documentation for prior authorization must include a provider-signed request form plus supporting clinical documentation. Submit relevant lab results, diagnostics, and chart notes to substantiate diagnosis, disease activity, prior therapy trials, and current medications.

Provider-signed request (physician signature required; preprinted stamps not valid)
Lab results confirming autoantibody-positive SLE (e.g., ANA ≥1:80, anti-dsDNA ≥30 IU/mL, or elevated anti-Smith)
Disease activity measures (e.g., SLEDAI-2K ≥6 or BILAG 2004 organ domain score ≥1A or ≥2B)
Chart notes or pharmacy claims verifying prior trials and current therapies

Documentation Required

Documentation Completeness and Sample Use

Documentation completeness and sample use: Incomplete or missing information (including unsigned forms, absent labs, unclear dates, or missing verification of prior trials) can delay or deny authorization. Provide clear, legible evidence rather than samples or incomplete summaries; all supporting documentation must be provided with the request.

Ensure phone and fax numbers on the form are correct to avoid unnecessary delays
Do not rely on incomplete summaries—attach full lab reports and chart notes
Samples alone are insufficient to demonstrate prior therapy trials

OpenPayer

Prior Authorization and Step-Edit Criteria for Saphnelo (anifrolumab) IV Infusion

Coverage Criteria for Saphnelo (anifrolumab) IV

Coding, Dosing, and Clinical Thresholds

Provider Requirements and Prior Authorization Workflow

Background on Saphnelo (anifrolumab)

Definitions and Clinical Terms